SHANIPV

Indications

• Constipation
• Irritable bowel syndrome
• Diverticular disease
• Prevention of straining during defecation post-surgery
• Management of stool consistency in patients with fecal incontinence

Dosage

Children: Refer to specific product guidelines for dosing information, as doses may vary depending on the formulation and the child's age and condition.

Adults: Refer to specific product guidelines for dosing information, as doses may vary depending on the formulation and the patient's condition.

Mechanism of action

Bulk-forming agents function by absorbing water in the intestinal lumen, which increases the stool volume. This mechanical effect stretches the intestinal walls, stimulating peristalsis and facilitating bowel movement. Additionally, the hydrated bulk can help to improve stool consistency and reduce the incidence of straining during defecation.

Pharmacodynamics

The pharmacodynamic effects of bulk-forming agents are primarily localized to the gastrointestinal tract. They increase stool bulk and moisture content, which can help to alleviate constipation. The onset of action typically occurs within 12 to 72 hours after ingestion, depending on the specific agent and individual patient factors.

Pharmacokinetics

Bulk-forming agents are not absorbed into the bloodstream and remain within the gastrointestinal tract. They exert their effects locally and are eliminated in the feces. The hydration of the bulk-forming agent occurs within the intestinal lumen, which helps to form a gel-like substance that enhances stool passage without systemic absorption.

Adverse effects

• Gastrointestinal discomfort
• Bloating
• Flatulence
• Diarrhea
• Nausea

Precautions

• Ensure adequate fluid intake to prevent gastrointestinal obstruction.
• Monitor for signs of allergic reactions in sensitive individuals.
• Use cautiously in patients with gastrointestinal disorders.

Pregnancy

Generally considered safe, but consult a healthcare provider for individual assessment.

Breast-feeding

Considered safe, but consult a healthcare provider for individual assessment.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Formulations

• Powder
• Capsules
• Tablets
• Granules

Dosage

Children: Refer to specific product guidelines as dosages may vary based on the active ingredient and clinical condition.

Adults: Refer to specific product guidelines as dosages may vary based on the active ingredient and clinical condition.

Mechanism of action

The specific mechanism of action for a concentrated drug depends on the active ingredients present in the formulation. Generally, concentrated drugs exert their effects by interacting with specific receptors or enzymes in the body, altering physiological processes. For example, concentrated analgesics may inhibit cyclooxygenase enzymes, leading to reduced production of prostaglandins, resulting in pain relief. Similarly, concentrated antibiotics may inhibit bacterial cell wall synthesis, leading to bacterial death.

Pharmacodynamics

Pharmacodynamics of concentrated drugs involves understanding the relationship between drug concentration at the site of action and the resulting therapeutic effect. Concentration-dependent effects may be observed, where higher concentrations lead to increased efficacy but also a risk of toxicity. The therapeutic window, which is the range between effective and toxic concentrations, is critical in guiding the safe use of concentrated formulations.

Pharmacokinetics

Pharmacokinetics of concentrated drugs encompasses absorption, distribution, metabolism, and excretion (ADME). Concentrated formulations may have altered pharmacokinetic profiles compared to standard formulations due to their higher potency. Absorption may be faster or more extensive, depending on the formulation. Distribution may be influenced by factors such as lipophilicity and plasma protein binding. Metabolism may occur in the liver, primarily through enzymatic pathways, while excretion typically occurs via renal or biliary routes.

Pregnancy

Consult a healthcare professional before use. Safety in pregnancy has not been established.

Breast-feeding

Consult a healthcare professional before use. Safety during breastfeeding has not been established.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Indications

• Hepatitis A
• Hepatitis B
• Influenza
• Polio
• Rabies
• Typhoid fever

Dosage

Children: Refer to specific product guidelines for paediatric dosing, as it varies by vaccine type and indication.

Adults: Refer to specific product guidelines for adult dosing, as it varies by vaccine type and indication.

Mechanism of action

Inactivated vaccines work by introducing a form of the pathogen that cannot cause disease into the body. This stimulates the immune system to produce antibodies and memory cells specific to the pathogen, allowing for a robust immune response upon future exposure. The immune system recognizes the inactivated pathogen as foreign, leading to the activation of T-cells and B-cells, which are crucial for long-term immunity.

Pharmacodynamics

The pharmacodynamics of inactivated vaccines involve the generation of an adaptive immune response. After vaccination, the body produces specific antibodies against the inactivated pathogen. The response typically includes both humoral immunity, characterized by antibody production, and cellular immunity, involving T-cell activation. The duration of immunity can vary, and booster doses may be required to maintain adequate protection.

Pharmacokinetics

Inactivated vaccines do not have a pharmacokinetic profile like traditional drugs since they do not enter systemic circulation in the same manner. Following administration, the vaccine components are taken up by antigen-presenting cells, which process and present the antigens to T-cells. The immune response is initiated locally at the site of injection and can be influenced by factors such as the route of administration and the presence of adjuvants that enhance the immune response.

Adverse effects

• Injection site reactions (pain, swelling, redness)
• Fever
• Fatigue
• Headache
• Myalgia
• Chills

Precautions

• Assess for allergies to vaccine components
• Monitor for allergic reactions post-administration
• Consider underlying health conditions that may affect immune response

Pregnancy

Inactivated vaccines are generally considered safe during pregnancy, but individual risk-benefit assessment is recommended.

Breast-feeding

Inactivated vaccines can be administered during breastfeeding without concern for adverse effects in the infant.

Storage

Store in a refrigerator at 2°C to 8°C. Do not freeze.

Formulations

• Inactivated viral vaccines
• Inactivated bacterial vaccines

Indications

• Prevention of poliomyelitis
• Vaccination in children according to immunization schedules
• Post-exposure prophylaxis in outbreak situations

Dosage

Children: Refer to local guidelines for specific dosing recommendations based

Adults: Refer to local guidelines for specific dosing recommendations based on immunization protocols.

Mechanism of action

The poliovaccine induces an immune response by introducing inactivated or attenuated poliovirus antigens into the body. This exposure prompts the immune system to produce specific antibodies that provide protection against future infections by the poliovirus. The mechanism involves the activation of T and B lymphocytes, resulting in both humoral and cellular immunity. The antibodies generated neutralize the virus and prevent its replication within the host.

Pharmacodynamics

The pharmacodynamics of the poliovaccine involves the generation of a robust immune response that includes the production of neutralizing antibodies, which are crucial for preventing the poliovirus from causing infection. Upon vaccination, the body recognizes the vaccine components as foreign, leading to a cascade of immune responses that enhance the host's ability to fight off the actual virus if exposed in the future. The vaccine has demonstrated high efficacy in preventing poliomyelitis, with widespread vaccination contributing to the near-eradication of the disease in many regions.

Pharmacokinetics

The pharmacokinetics of the poliovaccine varies depending on the formulation. For IPV, it is injected intramuscularly and rapidly induces an immune response, with peak antibody levels typically achieved within a few weeks. For OPV, it is administered orally, where it replicates in the intestine, leading to a mucosal immune response. The duration of immunity provided by the vaccine is long-lasting, though periodic booster doses may be recommended to maintain immunity, particularly in areas where poliovirus is still circulating.

Contra-indications

• Severe allergic reaction to any component of the vaccine
• Severe immunodeficiency (e.g., in patients with certain cancers or on immunosuppressive therapy)
• Pregnancy (in the case of live attenuated vaccine)

Adverse effects

• Fever
• Fatigue
• Mild allergic reactions (e.g., rash, itching)
• Injection site reactions (e.g., pain, redness, swelling)
• Rarely, vaccine-derived poliovirus infections in immunocompromised individuals

Interactions

• Live vaccines may interact with immunosuppressive therapies, reducing their effectiveness
• Concurrent administration with other vaccines is generally safe; however, specific guidance should be followed

Precautions

• Assess for any history of allergic reactions to vaccine components
• Monitor for adverse reactions following vaccination, especially in immunocompromised individuals
• Consider the patient's immunization history before administration

Pregnancy

The inactivated poliovirus vaccine (IPV) is considered safe during pregnancy. However, live attenuated polio vaccine (OPV) is contraindicated.

Breast-feeding

The inactivated poliovirus vaccine (IPV) can be administered during breastfeeding; live attenuated polio vaccine (OPV) should be used with caution.

Storage

Store in a refrigerator at 2°C to 8°C. Do not freeze. Protect from light.

Formulations

• Inactivated poliovirus vaccine (IPV)
• Oral poliovirus vaccine (OPV)

Indications

• Influenza prevention
• Diphtheria prevention
• Tetanus prevention
• Pertussis prevention

Dosage

Children: Refer to specific vaccine guidelines for paediatric dosing, as it varies by vaccine type and indication.

Adults: Refer to specific vaccine guidelines for adult dosing, as it varies by vaccine type and indication.

Mechanism of action

Trivalent vaccines function by introducing inactivated or attenuated forms of three different strains of a pathogen into the body, stimulating an immune response. This process activates B-cells to produce antibodies specific to the strains present in the vaccine. The immune system then remembers these strains, enabling a quicker and more effective response upon future exposure.

Pharmacodynamics

The pharmacodynamics of trivalent vaccines involve the induction of both humoral and cellular immunity. Upon vaccination, the immune system generates antibodies against the three strains, leading to neutralization of the pathogens. Additionally, T-helper cells are activated, promoting the proliferation of B-cells and the formation of memory cells, which provide long-term immunity.

Pharmacokinetics

Trivalent vaccines have a unique pharmacokinetic profile as they are not absorbed or distributed like traditional pharmacological agents. Instead, they are administered via injection, leading to localized immune activation. The onset of immune response typically occurs within two weeks post-vaccination, with peak antibody levels reached within one to two months. The duration of immunity can vary, requiring booster doses for sustained protection.

Adverse effects

• Injection site reactions
• Fever
• Malaise
• Fatigue
• Headache
• Myalgia
• Nausea

Precautions

• Use with caution in individuals with a history of allergic reactions to vaccine components
• Monitor for allergic reactions post-vaccination
• Consider underlying conditions that may affect immune response

Pregnancy

Generally considered safe, but consult healthcare provider for individual assessment.

Breast-feeding

Typically safe, but consult healthcare provider for individual assessment.

Storage

Store in a refrigerator at 2-8 degrees Celsius, do not freeze.

Formulations

• Trivalent inactivated influenza vaccine
• Trivalent live attenuated influenza vaccine

Indications

• Allergic conditions
• Autoimmune diseases
• Inflammatory conditions
• Certain cancers
• Asthma exacerbations
• Chronic obstructive pulmonary disease (COPD)

Dosage

Children: Refer to the BNF for Children for pediatric dosing recommendations, as these will depend on the child's age, weight, and specific clinical condition.

Adults: Refer to the specific BNF for appropriate dosing information based on the condition being treated. Dosage varies widely depending on the severity of the condition and the specific formulation used.

Mechanism of action

Dexamethasone binds to glucocorticoid receptors in the cytoplasm of target cells, leading to the formation of a receptor-hormone complex that translocates to the nucleus. This complex then modulates gene expression, resulting in the inhibition of pro-inflammatory cytokines and mediators, thus exerting potent anti-inflammatory and immunosuppressive effects.

Pharmacodynamics

Dexamethasone exhibits anti-inflammatory properties by reducing the migration of leukocytes and the production of cytokines. It suppresses the immune response and decreases capillary permeability, which helps in alleviating symptoms associated with inflammation. Its effects can be observed in various conditions, including autoimmune disorders, asthma, and as part of anti-cancer regimens.

Pharmacokinetics

Dexamethasone is rapidly absorbed when administered orally and reaches peak plasma concentrations within 1 to 2 hours. It has a high protein binding rate, primarily to albumin and corticosteroid-binding globulin. The drug is metabolized predominantly in the liver and has a half-life of approximately 3 to 4 hours. It is excreted mainly through urine as metabolites.

Pregnancy

Safety during pregnancy has not been established. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is unknown whether vero is excreted in human milk. Caution should be exercised when administered to nursing women.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.